RECK and lung carcinoma: In lung cancer, LXY30 peptide–modified bone marrow mesenchymal stromal cells (MSCs) exosomes loaded with miR-30c, miR-181b, or miR-613 selectively targeted NSCLC, suppressing proliferation/migration and inducing apoptosis with in vivo safety, while underscoring the value of integrin-directed targeting [88]; conversely, Schwann cell–derived exosome miR-21-5p drives lung cancer growth and metastasis by repressing RECK, rationalizing anti–miR-21 or source-targeted interception strategies [89].